1
|
Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, Vordos D, Guy L, Villers A, Schneider M, Coloby P, Lacoste J, Méjean A, Lacoste J, Descotes JL, Eschwege P, Loison G, Blanché H, Mariani O, Ghaleh B, Mangin A, Sirab N, Groussard K, Radvanyi F, Allory Y, Benhamou S. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. BMJ Open 2023; 13:e075942. [PMID: 38128940 DOI: 10.1136/bmjopen-2023-075942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2023] Open
Abstract
PURPOSE Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting. PARTICIPANTS COBLAnCE (COhort to study BLAdder CancEr) is a French national prospective cohort of patients with bladder cancer recruited between 2012 and 2018 and followed for 6 years. Data on patient and tumour characteristics, treatments, outcomes and biological samples are collected at enrolment and during the follow-up. FINDINGS TO DATE We describe the cohort at enrolment according to baseline surgery and tumour type. In total, 1800 patients were included: 1114 patients with non-muscle-invasive bladder cancer (NMIBC) and 76 patients with muscle-invasive bladder cancer (MIBC) had transurethral resection of a bladder tumour without cystectomy, and 610 patients with NMIBC or MIBC underwent cystectomy. Most patients had a solitary lesion (56.3%) without basement membrane invasion (71.7% of Ta and/or Tis). Half of the patients with cystectomy were stage ≤T2 and 60% had non-continent diversion. Surgery included local (n=298) or super-extended lymph node dissections (n=11) and prostate removal (n=492). Among women, 16.5% underwent cystectomy and 81.4% anterior pelvectomy. FUTURE PLANS COBLAnCE will be used for long-term studies of bladder cancer with focus on clinicopathological factors and molecular markers. It will lead to a much-needed improvement in the understanding of the disease. The cohort provides valuable real-world data, enabling researchers to study various research questions, assess routine medical practices and guide medical decision-making.
Collapse
Affiliation(s)
| | - Julia Bonastre
- Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
| | - Aldéric Fraslin
- Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
| | | | - Stéphane Droupy
- Urology, Centre Hospitalier Universitaire de Nimes, Nimes, France
| | | | - Dimitri Vordos
- Clinical Investigation Center 1430, INSERM, Créteil, France
| | - Laurent Guy
- Urology, University Hospital Centre Gabriel Montpied, Clermont-Ferrand, France
| | | | | | - Patrick Coloby
- Urology, University Hospital Center René Dubos, Cergy-Pontoise, France
| | - Jean Lacoste
- Urology, Private Hospital of Provence, Aix-en-Provence, France
| | - Arnaud Méjean
- Urology, Hopital Europeen Georges Pompidou, Paris, France
| | | | | | - Pascal Eschwege
- Urology, CHU de Nancy Hôpital de Brabois Adultes, Vandoeuvre-les-Nancy, France
| | | | | | - Odette Mariani
- Biological Resources Center, Curie Institute Hospital Group, Paris, France
| | - Bijan Ghaleh
- Biological Resources Platform, Hôpital Henri Mondor, Creteil, France
| | - Anthony Mangin
- Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
| | | | | | | | - Yves Allory
- Patholgy, Curie Institute Saint Cloud, Saint-Cloud, France
| | | |
Collapse
|
2
|
Karimi M, Mendez-Pineda S, Blanché H, Boland A, Besse C, Deleuze JF, Meng XY, Sirab N, Groussard K, Lebret T, Bonastre J, Allory Y, Radvanyi F, Benhamou S, Michiels S. A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort. Cancers (Basel) 2023; 15:4218. [PMID: 37686494 PMCID: PMC10487226 DOI: 10.3390/cancers15174218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 08/02/2023] [Accepted: 08/07/2023] [Indexed: 09/10/2023] Open
Abstract
Bladder cancer (BC) is the 6th most common cancer worldwide, with tobacco smoking considered as its main risk factor. Accumulating evidence has found associations between genetic variants and the risk of BC. Candidate gene-environment interaction studies have suggested interactions between cigarette smoking and NAT2/GSTM1 gene variants. Our objective was to perform a genome-wide association case-only study using the French national prospective COBLAnCE cohort (COhort to study BLAdder CancEr), focusing on smoking behavior. The COBLAnCE cohort comprises 1800 BC patients enrolled between 2012 and 2018. Peripheral blood samples collected at enrolment were genotyped using the Illumina Global Screening Array with a Multi-Disease drop-in panel. Genotyping data (9,719,614 single nucleotide polymorphisms (SNP)) of 1674, 1283, and 1342 patients were analyzed for smoking status, average tobacco consumption, and age at smoking initiation, respectively. A genome-wide association study (GWAS) was conducted adjusting for gender, age, and genetic principal components. The results suggest new candidate loci (4q22.1, 12p13.1, 16p13.3) interacting with smoking behavior for the risk of BC. Our results need to be validated in other case-control or cohort studies.
Collapse
Affiliation(s)
- Maryam Karimi
- Oncostat U1018 Inserm, Équipe Labellisée Ligue Contre le Cancer, Université Paris-Saclay, 94805 Villejuif, France
- Bureau de Biostatistique et d’Épidémiologie, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
| | - Sebastian Mendez-Pineda
- Oncostat U1018 Inserm, Équipe Labellisée Ligue Contre le Cancer, Université Paris-Saclay, 94805 Villejuif, France
| | - Hélène Blanché
- CEPH-Biobank, Fondation Jean Dausset-CEPH, 75010 Paris, France
| | - Anne Boland
- Centre National de Recherche en Génomique Humaine (CNRGH), CEA, Université Paris-Saclay, 91057 Evry, France
| | - Céline Besse
- Centre National de Recherche en Génomique Humaine (CNRGH), CEA, Université Paris-Saclay, 91057 Evry, France
| | - Jean-François Deleuze
- CEPH-Biobank, Fondation Jean Dausset-CEPH, 75010 Paris, France
- Centre National de Recherche en Génomique Humaine (CNRGH), CEA, Université Paris-Saclay, 91057 Evry, France
| | | | - Nanor Sirab
- Curie Institute, CNRS, UMR144, Molecular Oncology Team, PSL Research University, 75005 Paris, France
| | - Karine Groussard
- Oncostat U1018 Inserm, Équipe Labellisée Ligue Contre le Cancer, Université Paris-Saclay, 94805 Villejuif, France
| | | | - Julia Bonastre
- Oncostat U1018 Inserm, Équipe Labellisée Ligue Contre le Cancer, Université Paris-Saclay, 94805 Villejuif, France
- Bureau de Biostatistique et d’Épidémiologie, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
| | - Yves Allory
- CNRS UMR144, Curie Institute, 75005 Paris, France
- UVSQ, Curie Institute, Department of Pathology, Université Paris-Saclay, 92210 Saint-Cloud, France
| | | | - Simone Benhamou
- Oncostat U1018 Inserm, Équipe Labellisée Ligue Contre le Cancer, Université Paris-Saclay, 94805 Villejuif, France
| | - Stefan Michiels
- Oncostat U1018 Inserm, Équipe Labellisée Ligue Contre le Cancer, Université Paris-Saclay, 94805 Villejuif, France
- Bureau de Biostatistique et d’Épidémiologie, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
| |
Collapse
|
3
|
Abstract
INTRODUCTION/OBJECTIVE DNA, RNA, and proteins are unavoidable human biomarkers. Today, blood remains the commonly used source of biomarkers despite numerous limitations. Therefore, other sources of biomarkers such as urine could be more appropriate for research in the field of bladder cancer. The aim of this study was to set up a new automated procedure for urinary DNA, RNA, and protein extraction and to evaluate their quality and quantity. MATERIALS AND METHODS This study was conducted in the setting of the COBLAnCE cohort. Urinary DNA and RNA were extracted using the Maxwell 16 system, and urinary proteins were isolated by precipitation from the supernatant and the cell pellet. The concentration and purity of nucleic acids were determined by spectrophotometry. RNA integrity was determined by the Agilent Bioanalyzer. PCR assays were also used to ensure the quality of DNA and RNA samples. The quality of protein samples obtained was determined by Western blot analysis. RESULTS PCR experiments performed highlighted that it is possible to use the DNA and RNA samples for amplification, gene expression, or genotyping. However, DNA and RNA recovery from urine was highly variable among patients, with a significant impact of the patient's gender. The samples were highly degraded. Finally, our protocol of protein isolation was effective in extracting urinary supernatant proteins as well as pellet proteins. DISCUSSION Therefore, urine samples could constitute valuable resources for subsequent investigations in bladder cancer. These samples will allow identifying new easy-access biomarkers for the early detection of cancer, monitoring cancer progression, and assessing response to therapy.
Collapse
Affiliation(s)
- Caroline Barau
- APHP, Hôpital Henri Mondor,
Plateforme de Ressources BiologiquesCréteilF-94000France
| | - Pascale Maillé
- APHP, Hôpital Henri Mondor,
Département de PathologieCréteilF-94000France
| | - Nanor Sirab
- APHP, Hôpital Henri Mondor,
Département de PathologieCréteilF-94000France
| | - Bijan Ghaleh
- APHP, Hôpital Henri Mondor,
Plateforme de Ressources BiologiquesCréteilF-94000France
- ADDRESS CORRESPONDENCE TO: Bijan Ghaleh, Plateforme de Ressources
Biologiques, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de
Tassigny, 94000 Créteil (Phone: 33-1-49813796; E-mail:
)
| | - Yves Allory
- Institut Curie,
CNRS, UMR 144Paris75248France
| |
Collapse
|
4
|
Cuadrado‐Vilanova M, Liu J, Paco S, Aschero R, Burgueño V, Sirab N, Pascual‐Pasto G, Correa G, Balaguer‐Lluna L, Castillo‐Ecija H, Perez‐Jaume S, Muñoz‐Aznar O, Roldan M, Suñol M, Schaiquevich P, Aerts I, Doz F, Cassoux N, Lubieniecki F, Benitez‐Ribas D, Lavarino C, Mora J, Chantada GL, Catala‐Mora J, Radvanyi F, Carcaboso AM. Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. J Pathol 2022; 257:327-339. [DOI: 10.1002/path.5893] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 02/10/2022] [Accepted: 03/03/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Maria Cuadrado‐Vilanova
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Jing Liu
- Institut Curie, CNRS, UMR144, SIREDO Oncology Center Paris France
- Institut Curie PSL Research University Paris France
| | - Sonia Paco
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Rosario Aschero
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Victor Burgueño
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Nanor Sirab
- Institut Curie, CNRS, UMR144, SIREDO Oncology Center Paris France
- Institut Curie PSL Research University Paris France
| | - Guillem Pascual‐Pasto
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Genoveva Correa
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Leire Balaguer‐Lluna
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Helena Castillo‐Ecija
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Sara Perez‐Jaume
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Oscar Muñoz‐Aznar
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Monica Roldan
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Genetic and Molecular Medicine ‐ IPER, Hospital Sant Joan de Deu, Esplugues de Llobregat Barcelona Spain
| | - Mariona Suñol
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pathology, Hospital Sant Joan de Deu Barcelona Spain
| | - Paula Schaiquevich
- Precision Medicine, Hospital de Pediatria JP Garrahan Buenos Aires Argentina
- CONICET Buenos Aires Argentina
| | - Isabelle Aerts
- Institut Curie, CNRS, UMR144, SIREDO Oncology Center Paris France
| | - François Doz
- Institut Curie, CNRS, UMR144, SIREDO Oncology Center Paris France
- University of Paris Paris France
| | - Nathalie Cassoux
- University of Paris Paris France
- Institut Curie, Ophthalmic Oncology Paris France
| | | | | | - Cinzia Lavarino
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Jaume Mora
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| | - Guillermo L. Chantada
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
- CONICET Buenos Aires Argentina
- Universidad Austral‐CONICET Institute for Research in Translational Medicine (IIMT) Pilar Argentina
| | | | - François Radvanyi
- Institut Curie, CNRS, UMR144, SIREDO Oncology Center Paris France
- Institut Curie PSL Research University Paris France
| | - Angel M. Carcaboso
- Institut de Recerca Sant Joan de Deu Barcelona Spain
- Pediatric Oncology, Hospital Sant Joan de Deu Barcelona Spain
| |
Collapse
|
5
|
Sirab N, Drubay D, Maillé P, Popova T, Ngo C, Gentien D, Moktefi A, Soyeux-Porte P, Pelletier R, Reyes C, Henry E, Pouessel D, Vordos D, Lebret T, de Reyniès A, Paoletti X, Radvanyi F, Allory Y. Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. J Pathol 2021; 256:108-118. [PMID: 34611919 DOI: 10.1002/path.5813] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Revised: 09/23/2021] [Accepted: 10/01/2021] [Indexed: 12/12/2022]
Abstract
Basal/squamous (Ba/Sq) subtype represents an intrinsic and robust group in the consensus molecular classification of muscle-invasive bladder cancer (MIBC), with poor outcome and controversial chemosensitivity. We aimed to investigate the spectrum of intratumor heterogeneity (ITH) in the Ba/Sq subtype. First, we validated a 29-gene NanoString CodeSet to predict the Ba/Sq subtype for FFPE samples. We identified heterogeneous Ba/Sq tumors in a series of 331 MIBC FFPE samples using dual GATA3/KRT5/6 immunohistochemistry (IHC). Heterogeneous regions with distinct immunostaining patterns were studied separately for gene expression using the 29-gene CodeSet, for mutations by targeted next-generation sequencing, and for copy number alteration (CNA) by microarray hybridization. Among 83 Ba/Sq tumors identified by GATA3/KRT5/6 dual staining, 19 tumors showed heterogeneity at the IHC level. In one third of the 19 cases, regions from the same tumor were classified in different distinct molecular subtypes. The mutational and CNA profiles confirmed the same clonal origin for IHC heterogeneous regions with possible subclonal evolution. Overall, two patterns of intratumoral heterogeneity (ITH) were observed in Ba/Sq tumors: low ITH (regions with distinct immunostaining, but common molecular subtype and shared CNA) or high ITH (regions with distinct immunostaining, molecular subtype, and CNA). These results showed multilayer heterogeneity in Ba/Sq MIBC. In view of personalized medicine, this heterogeneity adds complexity and should be taken into account for sampling procedures used for diagnosis and treatment choice. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Nanor Sirab
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Damien Drubay
- Gustave Roussy, Service de Biostatistique et d'Epidémiologie, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, France
| | - Pascale Maillé
- Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Tatiana Popova
- Institut Curie, INSERM, U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Paris, France
| | - Carine Ngo
- Université Paris-Est, U955 INSERM, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - David Gentien
- Institut Curie, Translational Research Department, Genomic Platform, PSL Research University, Paris, France
| | - Anissa Moktefi
- Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Pascale Soyeux-Porte
- Université Paris-Est, U955 INSERM, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - Romain Pelletier
- Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Cécile Reyes
- Institut Curie, Translational Research Department, Genomic Platform, PSL Research University, Paris, France
| | - Emilie Henry
- Institut Curie, Translational Research Department, Genomic Platform, PSL Research University, Paris, France
| | - Damien Pouessel
- Department of Medical Oncology, Institut Universitaire du Cancer Oncopole de Toulouse, Toulouse, France
| | - Dimitri Vordos
- Department of Urology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Thierry Lebret
- Department of Urology, Hôpital Foch, Suresnes, France.,Université de Versailles-Saint-Quentin-en-Yvelines, UFR Santé Simone Veil, Guyancourt, France
| | - Aurélien de Reyniès
- Ligue Nationale Contre Le Cancer, Cartes D'Identité Des Tumeurs Program, Paris, France
| | - Xavier Paoletti
- Université de Versailles-Saint-Quentin-en-Yvelines, UFR Santé Simone Veil, Guyancourt, France.,Institut Curie, INSERM, U900, Statistical Methods for Precision Medicine (StaMPM), Saint-Cloud, France
| | - François Radvanyi
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Yves Allory
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.,Université de Versailles-Saint-Quentin-en-Yvelines, UFR Santé Simone Veil, Guyancourt, France.,Department of Pathology, Institut Curie, Saint-Cloud, France
| |
Collapse
|
6
|
Liu J, Ottaviani D, Sefta M, Desbrousses C, Chapeaublanc E, Aschero R, Sirab N, Lubieniecki F, Lamas G, Tonon L, Dehainault C, Hua C, Fréneaux P, Reichman S, Karboul N, Biton A, Mirabal-Ortega L, Larcher M, Brulard C, Arrufat S, Nicolas A, Elarouci N, Popova T, Némati F, Decaudin D, Gentien D, Baulande S, Mariani O, Dufour F, Guibert S, Vallot C, Rouic LLL, Matet A, Desjardins L, Pascual-Pasto G, Suñol M, Catala-Mora J, Llano GC, Couturier J, Barillot E, Schaiquevich P, Gauthier-Villars M, Stoppa-Lyonnet D, Golmard L, Houdayer C, Brisse H, Bernard-Pierrot I, Letouzé E, Viari A, Saule S, Sastre-Garau X, Doz F, Carcaboso AM, Cassoux N, Pouponnot C, Goureau O, Chantada G, de Reyniès A, Aerts I, Radvanyi F. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nat Commun 2021; 12:5578. [PMID: 34552068 PMCID: PMC8458383 DOI: 10.1038/s41467-021-25792-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 08/26/2021] [Indexed: 02/06/2023] Open
Abstract
Retinoblastoma is the most frequent intraocular malignancy in children, originating from a maturing cone precursor in the developing retina. Little is known on the molecular basis underlying the biological and clinical behavior of this cancer. Here, using multi-omics data, we demonstrate the existence of two retinoblastoma subtypes. Subtype 1, of earlier onset, includes most of the heritable forms. It harbors few genetic alterations other than the initiating RB1 inactivation and corresponds to differentiated tumors expressing mature cone markers. By contrast, subtype 2 tumors harbor frequent recurrent genetic alterations including MYCN-amplification. They express markers of less differentiated cone together with neuronal/ganglion cell markers with marked inter- and intra-tumor heterogeneity. The cone dedifferentiation in subtype 2 is associated with stemness features including low immune and interferon response, E2F and MYC/MYCN activation and a higher propensity for metastasis. The recognition of these two subtypes, one maintaining a cone-differentiated state, and the other, more aggressive, associated with cone dedifferentiation and expression of neuronal markers, opens up important biological and clinical perspectives for retinoblastomas.
Collapse
Affiliation(s)
- Jing Liu
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
- Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, 75013, Paris, France
| | - Daniela Ottaviani
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
- Precision Medicine, Hospital J.P. Garrahan, Buenos Aires, Argentina
| | - Meriem Sefta
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | - Céline Desbrousses
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | - Elodie Chapeaublanc
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | - Rosario Aschero
- Pathology Service, Hospital J.P. Garrahan, Buenos Aires, Argentina
| | - Nanor Sirab
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | | | - Gabriela Lamas
- Pathology Service, Hospital J.P. Garrahan, Buenos Aires, Argentina
| | - Laurie Tonon
- Synergie Lyon Cancer, Plateforme de Bioinformatique "Gilles Thomas", Centre Léon Bérard, 69008, Lyon, France
| | - Catherine Dehainault
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
- Service de Génétique, Institut Curie, 75005, Paris, France
| | - Clément Hua
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | - Paul Fréneaux
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
| | - Sacha Reichman
- Institut de la Vision, Sorbonne Université, INSERM, CNRS, 75012, Paris, France
| | - Narjesse Karboul
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | - Anne Biton
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
- Institut Curie, PSL Research University, INSERM, U900, 75005, Paris, France
- Ecole des Mines ParisTech, 77305, Fontainebleau, France
- Institut Pasteur - Hub Bioinformatique et Biostatistique - C3BI, USR 3756 IP CNRS, 75015, Paris, France
| | - Liliana Mirabal-Ortega
- Institut Curie, CNRS, UMR3347, PSL Research University, 91405, Orsay, France
- Institut Curie, PSL Research University, INSERM, U1021, 91405, Orsay, France
- Université Paris-Saclay, 91405, Orsay, France
| | - Magalie Larcher
- Institut Curie, CNRS, UMR3347, PSL Research University, 91405, Orsay, France
- Institut Curie, PSL Research University, INSERM, U1021, 91405, Orsay, France
- Université Paris-Saclay, 91405, Orsay, France
| | - Céline Brulard
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
- INSERM U930, CHU Bretonneau, 37000, Tours, France
| | - Sandrine Arrufat
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
| | - André Nicolas
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
| | - Nabila Elarouci
- Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, 75013, Paris, France
| | - Tatiana Popova
- Institut Curie, PSL Research University, INSERM U830, 75005, Paris, France
| | - Fariba Némati
- Département de Recherche Translationnelle, Institut Curie, 75005, Paris, France
| | - Didier Decaudin
- Département de Recherche Translationnelle, Institut Curie, 75005, Paris, France
| | - David Gentien
- Département de Recherche Translationnelle, Institut Curie, 75005, Paris, France
| | - Sylvain Baulande
- Institut Curie, PSL Research University, NGS Platform, 75005, Paris, France
| | - Odette Mariani
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
| | - Florent Dufour
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | | | - Céline Vallot
- GeCo Genomics Consulting, Integragen, 91000, Evry, France
| | | | - Alexandre Matet
- Département de Chirurgie, Service d'Ophtalmologie, Institut Curie, 75005, Paris, France
- Université de Paris, Paris, France
| | - Laurence Desjardins
- Département de Chirurgie, Service d'Ophtalmologie, Institut Curie, 75005, Paris, France
| | - Guillem Pascual-Pasto
- Institut de Recerca Sant Joan de Déu, 08950, Barcelona, Spain
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950, Barcelona, Spain
| | - Mariona Suñol
- Institut de Recerca Sant Joan de Déu, 08950, Barcelona, Spain
- Department of Pathology, Hospital Sant Joan de Déu, 08950, Barcelona, Spain
| | - Jaume Catala-Mora
- Institut de Recerca Sant Joan de Déu, 08950, Barcelona, Spain
- Department of Ophthalmology, Hospital Sant Joan de Déu, 08950, Barcelona, Spain
| | - Genoveva Correa Llano
- Institut de Recerca Sant Joan de Déu, 08950, Barcelona, Spain
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950, Barcelona, Spain
| | - Jérôme Couturier
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
| | - Emmanuel Barillot
- Institut Curie, PSL Research University, INSERM, U900, 75005, Paris, France
- Ecole des Mines ParisTech, 77305, Fontainebleau, France
| | - Paula Schaiquevich
- Pathology Service, Hospital J.P. Garrahan, Buenos Aires, Argentina
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Marion Gauthier-Villars
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
- Service de Génétique, Institut Curie, 75005, Paris, France
- Institut Curie, PSL Research University, INSERM U830, 75005, Paris, France
| | - Dominique Stoppa-Lyonnet
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
- Service de Génétique, Institut Curie, 75005, Paris, France
- Université de Paris, Paris, France
| | - Lisa Golmard
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
- Service de Génétique, Institut Curie, 75005, Paris, France
- Institut Curie, PSL Research University, INSERM U830, 75005, Paris, France
| | - Claude Houdayer
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
- Service de Génétique, Institut Curie, 75005, Paris, France
- Institut Curie, PSL Research University, INSERM U830, 75005, Paris, France
- Department of Genetics, Rouen University Hospital, 76000, Rouen, France
| | - Hervé Brisse
- Département d'Imagerie Médicale, Institut Curie, 75005, Paris, France
| | - Isabelle Bernard-Pierrot
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
| | - Eric Letouzé
- Centre de Recherche des Cordeliers, Sorbonne Universités, INSERM, 75006, Paris, France
- Functional Genomics of Solid Tumors, équipe labellisée Ligue Contre le Cancer, Université de Paris, Université Paris 13, Paris, France
| | - Alain Viari
- Synergie Lyon Cancer, Plateforme de Bioinformatique "Gilles Thomas", Centre Léon Bérard, 69008, Lyon, France
| | - Simon Saule
- Institut Curie, CNRS, UMR3347, PSL Research University, 91405, Orsay, France
- Institut Curie, PSL Research University, INSERM, U1021, 91405, Orsay, France
- Université Paris-Saclay, 91405, Orsay, France
| | - Xavier Sastre-Garau
- Département de Biologie des Tumeurs, Institut Curie, 75005, Paris, France
- Department of Pathology, Centre Hospitalier Intercommunal de Créteil, 94000, Créteil, France
| | - François Doz
- Université de Paris, Paris, France
- SIREDO Center (Care, Innovation and Research in Pediatric Adolescent and Young Adult Oncology), Institut Curie, 75005, Paris, France
| | - Angel M Carcaboso
- Institut de Recerca Sant Joan de Déu, 08950, Barcelona, Spain
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950, Barcelona, Spain
| | - Nathalie Cassoux
- Département de Chirurgie, Service d'Ophtalmologie, Institut Curie, 75005, Paris, France
- Université de Paris, Paris, France
| | - Celio Pouponnot
- Institut Curie, CNRS, UMR3347, PSL Research University, 91405, Orsay, France
- Institut Curie, PSL Research University, INSERM, U1021, 91405, Orsay, France
- Université Paris-Saclay, 91405, Orsay, France
| | - Olivier Goureau
- Institut de la Vision, Sorbonne Université, INSERM, CNRS, 75012, Paris, France
| | - Guillermo Chantada
- Precision Medicine, Hospital J.P. Garrahan, Buenos Aires, Argentina
- Institut de Recerca Sant Joan de Déu, 08950, Barcelona, Spain
- Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950, Barcelona, Spain
- National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
| | - Aurélien de Reyniès
- Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, 75013, Paris, France
| | - Isabelle Aerts
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France
- SIREDO Center (Care, Innovation and Research in Pediatric Adolescent and Young Adult Oncology), Institut Curie, 75005, Paris, France
| | - François Radvanyi
- Institut Curie, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, PSL Research University, 75005, Paris, France.
- Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR144, 75005, Paris, France.
| |
Collapse
|
7
|
van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MAS, Marquez M, Stoehr R, Zlotta AR, Eckstein M, Soorojebally Y, Roshani H, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? †. Eur Urol 2020; 78:682-687. [PMID: 32682615 DOI: 10.1016/j.eururo.2020.07.002] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 07/02/2020] [Indexed: 11/15/2022]
Abstract
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-invasive BC. We analyzed FGFR3 mutations, FGFR3, and p53 protein expression and assessed their prognostic value in a cohort of 1000 chemotherapy-naive radical cystectomy specimens. FGFR3 mutations were found in 11%, FGFR3 overexpression was found in 28%, and p53 overexpression was found in 69% of tumors. Among FGFR3 mutant tumors, 73% had FGFR3 overexpression versus 22% among FGFR3 wild-type tumors. FGFR3 mutations were significantly associated with lower pT stage, tumor grade, absence of carcinoma in situ, pN0, low-level p53, and longer disease-specific survival (DSS). FGFR3 overexpression was associated only with lower pT stage and tumor grade. Moreover, FGFR3 overexpression was not associated with DSS in patients with FGFR3 wild-type tumors. In conclusion, FGFR3 mutations identified patients with favorable BC at cystectomy. Our results suggest that FGFR3 mutations have a driver role and are functionally distinct from FGFR3 overexpression. Hence, patients with FGFR3 mutations would be more likely to benefit from anti-FGFR3 therapy. Ideally, further research is needed to test this hypothesis. PATIENT SUMMARY: Oncogenic fibroblast growth factor receptor 3 (FGFR3) mutations are very common in bladder cancer. In this report, we found that these FGFR3 mutations were associated with favorable features and prognosis of bladder cancer compared with patients with FGFR3 overexpressed tumors only. As a consequence, patients with FGFR3 mutant tumors would be more likely to benefit from anti-FGFR3 therapy than patients with FGFR3 protein overexpression only.
Collapse
Affiliation(s)
- Bas W G van Rhijn
- Departments of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada; Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.
| | - Laura S Mertens
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Roman Mayr
- Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - Peter J Bostrom
- Departments of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada; Department of Urology, Turku University Hospital and University of Turku, Turku, Finland
| | - Francisco X Real
- Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO) & CIBERONC, Madrid, Spain; Department of de Ciències Experimentals i de la Salut, University Pompeu Fabra, Barcelona, Spain
| | - Ellen C Zwarthoff
- Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
| | - Joost L Boormans
- Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
| | - Cheno Abas
- Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
| | - Geert J L H van Leenders
- Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands; Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
| | - Stefanie Götz
- Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - Katrin Hippe
- Department of Pathology, University Medical Center-Regensburg, Regensburg, Germany
| | - Simone Bertz
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nürnberg, Erlangen, Germany
| | - Yann Neuzillet
- Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Joyce Sanders
- Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Annegien Broeks
- Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Michiel S van der Heijden
- Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Michael A S Jewett
- Departments of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada
| | - Mirari Marquez
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Robert Stoehr
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nürnberg, Erlangen, Germany
| | - Alexandre R Zlotta
- Departments of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada
| | - Markus Eckstein
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nürnberg, Erlangen, Germany
| | - Yanish Soorojebally
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Hossain Roshani
- Department of Urology, Haga Ziekenhuis, The Hague, The Netherlands
| | - Maximilian Burger
- Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - Wolfgang Otto
- Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany
| | - François Radvanyi
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Nanor Sirab
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France
| | - Damien Pouessel
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France; Department of Medical Oncology, Claudius Regaud Institute, Toulouse University Cancer Center (IUCT) Oncopole, Toulouse, France
| | - Bernd Wullich
- Department of Urology & Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nürnberg, Erlangen, Germany
| | - Theo H van der Kwast
- Department of Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada
| | - Núria Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Arndt Hartmann
- Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nürnberg, Erlangen, Germany
| | - Yves Allory
- Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France; Department of Pathology, Institut Curie, Paris, France
| | - Tahlita C M Zuiverloon
- Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands; Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
| |
Collapse
|
8
|
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. Eur Urol 2020; 77:436-438. [PMID: 32037144 DOI: 10.1016/j.eururo.2019.12.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2019] [Accepted: 12/17/2019] [Indexed: 11/26/2022]
Affiliation(s)
- Aurélie Kamoun
- Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France.
| | - Aurélien de Reyniès
- Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France
| | - Yves Allory
- Department of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Gottfrid Sjödahl
- Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden
| | - A Gordon Robertson
- Canada's Michael Smith Genome Sciences Center, BC Cancer Agency, Vancouver, BC, Canada
| | - Roland Seiler
- Department of Urology, Bern University Hospital, Bern, Switzerland
| | - Katherine A Hoadley
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Clarice S Groeneveld
- Cartes d'Identité des Tumeurs (CIT) Program, Ligue Nationale Contre le Cancer, Paris, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France; Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil
| | - Hikmat Al-Ahmadie
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Woonyoung Choi
- Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
| | - Mauro A A Castro
- Bioinformatics and Systems Biology Laboratory, Federal University of Paraná, Polytechnic Center, Curitiba, Brazil
| | - Jacqueline Fontugne
- Department of Pathology, Institut Curie, Saint-Cloud, France; Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Pontus Eriksson
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Qianxing Mo
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Jordan Kardos
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Alexandre Zlotta
- Division of Urology, Department of Surgery, University of Toronto, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
| | - Arndt Hartmann
- Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany
| | - Colin P Dinney
- Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Joaquim Bellmunt
- Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA
| | - Thomas Powles
- Barts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK
| | - Núria Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain
| | - Keith S Chan
- Cedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA
| | - William Y Kim
- Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - David J McConkey
- Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA
| | - Peter C Black
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Lars Dyrskjøt
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
| | - Mattias Höglund
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Seth P Lerner
- Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
| | - Francisco X Real
- Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain
| | - François Radvanyi
- Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Mattias Aine
- Division of Molecular Hematology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
| | - Isabelle Bernard-Pierrot
- Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Bogdan Czerniak
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ewan A Gibb
- GenomeDx Biosciences Inc., Vancouver, BC, Canada
| | - Jaegil Kim
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - David J Kwiatkowski
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Thierry Lebret
- Department of Urology, University of Versailles-Saint-Quentin-en-Yvelines, Foch Hospital, Suresnes, France
| | - Fredrik Liedberg
- Division of Urological Research, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden
| | - A Arlene Siefker-Radtke
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nanor Sirab
- Department of Pathology, Institut Curie Hospital Group, Paris, France
| | - Ann Taber
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
| | - John N Weinstein
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
9
|
Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I. High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer. Mol Cancer Res 2018; 17:469-475. [DOI: 10.1158/1541-7786.mcr-18-0363] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 08/01/2018] [Accepted: 10/18/2018] [Indexed: 11/16/2022]
|
10
|
Allory Y, Sirab N, Drubay D, Gentien D, De Reyniès A, Albaud B, Kamoun A, Soyeux P, Maille P, Lebret T, Benhamou S, Paoletti X, Radvanyi F. Evaluation of a 29 gene classifier for basal/non basal prediction in muscle-invasive bladder cancer FFPE samples. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.6_suppl.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
467 Background: Recent and independent muscle-invasive bladder cancer (MIBC) molecular classifications identified the basal / squamous-like (BASQ) tumours as an intrinsic and robust subtype, with a poor outcome and possible chemosensitivity to cisplatin based regimen, making mandatory the development of a diagnostic tool for their identification in routine samples. Our study aimed to evaluate the diagnostic accuracy of a Nanostring classifier for tumor subtype prediction on FPPE specimens. Methods: Two series of MIBC were used (CIT n = 51 & Stransky n = 22) for which BASQ tumours were identified previously using Affymetrix transcriptome data obtained from frozen samples (Rebouissou, Science Trans Med 2014). 29 genes were selected to predict the basal subtype, RNA expression of matched frozen and FFPE samples was studied using Nanostring technology. To define the classifiers for Affymetrix, frozen and FFPE Nanostring expression matrix on CIT samples the centroid of each cluster was calculated using the expression of 29 genes. Internal validation used leave-one-out cross-validation to train and test the prediction accuracy of the new classifier. For external validation, the CIT samples were used as training set and the Stransky samples as validation set. Predictive accuracy expressed as percentage of correctly classified samples is provided. Results: Correlations between Affymetrix, frozen and FFPE Nanostring data set were checked for gene expression and samples. Using CIT samples as train and test set, the predictive accuracy for BASQ tumour identification was for Affymetrix, frozen Nanostring and FFPE Nanostring classifiers, 90.20% [78.59%; 96.74%], 88.24% [76.13%; 95.56%] and 92.16% [81.12%; 97.82%], respectively. Using training on CIT samples and test on Stransky samples, this predictive accuracy was 90.91% [70.84%; 98.88%] both for Affymetrix, frozen Nanostring and FFPE Nanostring classifiers. Conclusions: The 29 gene expression Nanostring codeset was able to identify reliably basal / squamous like tumours on FFPE samples from MIBC in comparison with the gold standard approach based on transcriptomic profile, appearing as a promising diagnostic tool.
Collapse
Affiliation(s)
| | - Nanor Sirab
- Institut Mondor de Recherches Biomédicales, Créteil, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Giton F, Sirab N, Franck G, Gervais M, Schmidlin F, Ali T, Allory Y, de la Taille A, Vacherot F, Loric S, Fiet J. Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. J Steroid Biochem Mol Biol 2015; 152:89-100. [PMID: 25958048 DOI: 10.1016/j.jsbmb.2015.05.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Revised: 04/24/2015] [Accepted: 05/04/2015] [Indexed: 11/24/2022]
Abstract
High plasma exposure to estrogens is often associated with prostate cancer. Reducing this phenomenon may present therapeutic benefits. The involvement of estrone sulphate (E1S), the most abundant circulating estrogen in men, has been partially studied in this age-related pathology. To investigate the consequences of plasma E1S overload on blood and prostate sex steroid levels and inflammatory tissue responses, young and middle-aged male rats were treated with E1S with or without steroid sulfatase (STS) inhibitor STX64 for 21 consecutive days. A plasma and prostate tissue steroid profile was determined. STS activity, mRNA expression of E1S organic anion transporting polypeptides (slco1a2, slco2b1, slco4a1) and pro-inflammatory cytokines (Il1-beta, Il6, TNF-alpha) were evaluated in prostate tissue according to age and treatment group. A significant correlation between plasma and prostate steroid levels related to hormone treatment was observed in all rat age groups. However, while the E1S level in prostate tissue increased in middle-aged treated rats (p<0.0001), no significant variation was observed in young treated rats. The protective effect of STX64 during E1S infusion was observed by the maintenance of low free estrogen concentrations in both plasma and tissue. However, this protection was not associated with mRNA expression stability of pro-inflammatory cytokines in older rat prostate. These results suggest that E1S uptake in rat prostate cells increases during aging. Therefore, if a similar phenomenon existed in men, preventively reducing the STS activity could be of interest to limit uptake of estrogens in prostate when high E1S plasma level is assayed.
Collapse
Affiliation(s)
- Frank Giton
- AP-HP, CIB GHU Sud Henri Mondor, Créteil 94000, France; INSERM, U955 eq07, Créteil 94000, France.
| | | | | | | | | | | | - Yves Allory
- AP-HP, CIB GHU Sud Henri Mondor, Créteil 94000, France; INSERM, U955 eq07, Créteil 94000, France
| | | | | | - Sylvain Loric
- AP-HP, CIB GHU Sud Henri Mondor, Créteil 94000, France; INSERM, U955 eq07, Créteil 94000, France
| | - Jean Fiet
- INSERM, U955 eq07, Créteil 94000, France
| |
Collapse
|
12
|
Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci 2013; 14:14301-20. [PMID: 23846725 PMCID: PMC3742245 DOI: 10.3390/ijms140714301] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 05/22/2013] [Accepted: 06/18/2013] [Indexed: 12/28/2022] Open
Abstract
Despite the high prevalence of histological Benign Prostatic Hypeplasia (BPH) in elderly men, little is known regarding the molecular mechanisms and networks underlying the development and progression of the disease. Here, we explored the effects of a phytotherapeutic agent, Lipidosterolic extract of the dwarf palm plant Serenoa repens (LSESr), on the mRNA gene expression profiles of two representative models of BPH, BPH1 cell line and primary stromal cells derived from BPH. Treatment of these cells with LSESr significantly altered gene expression patterns as assessed by comparative gene expression profiling on gene chip arrays. The expression changes were manifested three hours following in vitro administration of LSESr, suggesting a rapid action for this compound. Among the genes most consistently affected by LSESr treatment, we found numerous genes that were categorized as part of proliferative, apoptotic, and inflammatory pathways. Validation studies using quantitative real-time PCR confirmed the deregulation of genes known to exhibit key roles in these biological processes including IL1B, IL1A, CXCL6, IL1R1, PTGS2, ALOX5, GAS1, PHLDA1, IL6, IL8, NFkBIZ, NFKB1, TFRC, JUN, CDKN1B, and ERBB3. Subsequent analyses also indicated that LSESr treatment can impede the stimulatory effects of certain proinflammatory cytokines such as IL6, IL17, and IL15 in these cells. These results suggest that LSESr may be useful to treat BPH that manifest inflammation characteristics. This also supports a role for inflammation in BPH presumably by mediating the balance between apoptosis and proliferation.
Collapse
Affiliation(s)
- Nanor Sirab
- INSERM, Unité 955, Equipe 7, Créteil F-94000, France; E-Mails: (N.S.); (G.R.)
| | - Grégoire Robert
- INSERM, Unité 955, Equipe 7, Créteil F-94000, France; E-Mails: (N.S.); (G.R.)
- CHU de Bordeaux, Service d’urologie, Université Bordeaux Segalen, Bordeaux F-33076, France
| | | | - Aurélien Descazeaud
- Hôpital Dupuytren, CHU de Limoges, Service d’urologie, Limoges F-87000, France; E-Mail:
| | - Francis Vacherot
- INSERM, Unité 955, Equipe 7, Créteil F-94000, France; E-Mails: (N.S.); (G.R.)
- Faculté de Médecine, Université Paris Est Créteil, Créteil F-94000, France
- Authors to whom correspondence should be addressed; E-Mails: (F.V.); (A.T.); (S.T.); Tel.: +33-1-49-81-3656 (F.V.; A.T. & S.T.); Fax: +33-1-49-81-3533 (F.V.; A.T. & S.T.)
| | - Alexandre de la Taille
- INSERM, Unité 955, Equipe 7, Créteil F-94000, France; E-Mails: (N.S.); (G.R.)
- Faculté de Médecine, Université Paris Est Créteil, Créteil F-94000, France
- AP-HP, Hôpital H. Mondor–A. Chenevier, Service d’urologie F-94000, France
- Authors to whom correspondence should be addressed; E-Mails: (F.V.); (A.T.); (S.T.); Tel.: +33-1-49-81-3656 (F.V.; A.T. & S.T.); Fax: +33-1-49-81-3533 (F.V.; A.T. & S.T.)
| | - Stéphane Terry
- INSERM, Unité 955, Equipe 7, Créteil F-94000, France; E-Mails: (N.S.); (G.R.)
- Institute Curie, Centre de Recherche, CNRS UMR3244, Paris F-75248, France
- Authors to whom correspondence should be addressed; E-Mails: (F.V.); (A.T.); (S.T.); Tel.: +33-1-49-81-3656 (F.V.; A.T. & S.T.); Fax: +33-1-49-81-3533 (F.V.; A.T. & S.T.)
| |
Collapse
|
13
|
Sirab N, Terry S, Giton F, Caradec J, Chimingqi M, Moutereau S, Vacherot F, Taille ADL, Kouyoumdjian JC, Loric S. Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells. Int J Cancer 2012; 131:1297-306. [DOI: 10.1002/ijc.27384] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Accepted: 11/10/2011] [Indexed: 01/22/2023]
|
14
|
Affiliation(s)
- J Caradec
- INSERM U955, team 7, Créteil 94000, France
- Paris Est University, Créteil 94000, France
| | - N Sirab
- INSERM U955, team 7, Créteil 94000, France
- Paris Est University, Créteil 94000, France
| | - D Revaud
- INSERM U955, team 7, Créteil 94000, France
- Paris Est University, Créteil 94000, France
| | - C Keumeugni
- INSERM U955, team 7, Créteil 94000, France
- Paris Est University, Créteil 94000, France
| | - S Loric
- INSERM U955, team 7, Créteil 94000, France
- Paris Est University, Créteil 94000, France
- Henri Mondor University Hospital, Biochemistry and Genetics Department, Créteil 94000, France
| |
Collapse
|
15
|
Caradec J, Sirab N, Keumeugni C, Moutereau S, Chimingqi M, Matar C, Revaud D, Bah M, Manivet P, Conti M, Loric S. 'Desperate house genes': the dramatic example of hypoxia. Br J Cancer 2010; 102:1037-43. [PMID: 20179706 PMCID: PMC2844028 DOI: 10.1038/sj.bjc.6605573] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Microenvironmental conditions in normal or tumour tissues and cell lines may interfere on further biological analysis. To evaluate transcript variations carefully, it is common to use stable housekeeping genes (HKG) to normalise quantitative microarrays or real-time polymerase chain reaction results. However, recent studies argue that HKG fluctuate according to tissues and treatments. So, as an example of HKG variation under an array of conditions that are common in the cancer field, we evaluate whether hypoxia could have an impact on HKG expression. METHODS Expression of 10 commonly used HKG was measured on four cell lines treated with four oxygen concentrations (from 1 to 20%). RESULTS Large variations of HKG transcripts were observed in hypoxic conditions and differ along with the cell line and the oxygen concentration. To elect the most stable HKG, we compared the three statistical means based either on PCR cycle threshold coefficient of variation calculation or two specifically dedicated software. Nevertheless, the best HKG dramatically differs according to the statistical method used. Moreover, using, as a reference, absolute quantification of a target gene (here the proteinase activating receptor gene 1 (PAR1) gene), we show that the conclusions raised about PAR1 variation in hypoxia can totally diverge according to the selected HKG used for normalisation. CONCLUSION The choice of a valid HKG will determine the relevance of the results that will be further interpreted, and so it should be seriously considered. The results of our study confirm unambiguously that HKG variations must be precisely and systematically determined before any experiment for each situation, to obtain reliable normalised results in the experimental setting that has been designed. Indeed, such assay design, functional for all in vitro systems, should be carefully evaluated before any extension to other experimental models including in vivo ones.
Collapse
Affiliation(s)
- J Caradec
- INSERM, U955 EQ07, Paris Est University, Créteil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, De La Taille A. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009; 69:1774-80. [PMID: 19670242 PMCID: PMC2833181 DOI: 10.1002/pros.21027] [Citation(s) in RCA: 195] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
INTRODUCTION AND OBJECTIVES Prostatic inflammation could be a key component in prostate enlargement and benign prostatic hyperplasia (BPH) progression. Our aim was to characterize inflammatory cells infiltrate within BPH tissue and to correlate inflammation and clinical data. MATERIAL AND METHODS Inflammation was profiled on three clinical outcome tissue microarrays (TMAs), including 282 patients treated by surgery for a complicated and/or symptomatic BPH. Inflammation score was defined by combining six cytological parameters and five markers on immunohistochemistry (IHC). Cytological parameters were lymphocytes, macrophages, and polynuclears leukocytes infiltrates, and three glandular aspect modifications: glandular atrophy, glandular destruction, and tissue fibrosis. IHC markers were CD3, CD4, and CD8 decorating T-lymphocytes, CD20 decorating B-lymphocytes, and CD163 decorating macrophages. RESULTS The majority of patients had inflammatory cells infiltrating BPH tissues: 81% had T-lymphocytes markers (CD3), 52% had B-lymphocytes markers (CD20), and 82% had macrophages markers (CD163). IPSS score (21 vs. 12; P = 0.02) and prostate volume (77 cm(3) vs. 62 cm(3); P = 0.002) were significantly higher in patients with high-grade prostatic inflammation. CONCLUSION We characterized inflammatory cells infiltrate in a large cohort of surgically treated BPH specimens. The role of inflammation in BPH development was highlighted by the strong correlation between histological inflammation, IPSS, and prostate volume. Prostate enlargement due to chronic inflammatory process may progressively conduce to BPH progression. Therefore, inflammation is a therapeutic target for BPH.
Collapse
Affiliation(s)
- Grégoire Robert
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
- Service d'urologie
Pellegrin University HospitalDepartment of UrologyBordeaux-2 Victor Segalen UniversityBordeaux,FR
| | - Aurélien Descazeaud
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
- Service d'urologie
Dupuytren HospitalCHU de LimogesDepartment of UrologyF-87000 Limoges,FR
| | - Nathalie Nicolaïew
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
| | - Stéphane Terry
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
| | - Nanor Sirab
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
| | - Francis Vacherot
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
| | - Pascale Maillé
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
- Service d'anatomie pathologique
AP-HPHôpital Henri MondorUniversité Paris XII Val de MarneCréteil,FR
| | - Yves Allory
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
| | - Alexandre De La Taille
- Institut Mondor de Recherche Biomédicale
INSERM : U955Université Paris XII Val de MarneIFR10FR
- Service d'urologie
AP-HPHôpital Henri MondorUniversité Paris XII Val de Marne51, av du Maréchal de Tassigny, Créteil,FR
- * Correspondence should be adressed to: Alexandre De La Taille
| |
Collapse
|
17
|
Robert G, Descazeaud A, Allory Y, Nicolaiew N, Maille P, Terry S, Sirab N, Bastien L, Vacherot F, de la Taille A. INFLAMMATION IN PROSTATIC TISSUE IS ASSOCIATED WITH SYMPTOMATIC BPH, IPSS AND PROSTATE VOLUME! J Urol 2009. [DOI: 10.1016/s0022-5347(09)61424-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil Diez de Medina S, Moutereau S, Maillé P, Soyeux P, Abbou C, Salomon L, Vacherot F, de La Taille A, Loric S, Allory Y. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol 2008; 216:460-70. [PMID: 18825689 DOI: 10.1002/path.2427] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Recent studies have revealed the potential involvement of Hedgehog (Hh) signalling in proliferation and invasive behaviour of prostate carcinoma (PCa). The aim of this study was to specify the role of Sonic Hh (Shh), Desert Hh (Dhh) and Indian Hh (Ihh) in the natural history of PCa. Hh ligands expression was compared in primary hormone-naive PCa (HNPC), hormone-treated PCa (HTPC) and hormone-refractory PCa (HRPC), using immunohistochemistry. Shh and Dhh were expressed by both epithelial and stromal cells of prostate tissues. Ihh was only expressed by stromal cells. For the three ligands, mRNA and immunostaining were not correlated. In HNPC, Shh epithelial expression was significantly associated with high Gleason scores (p = 0.03), metastatic lymph nodes (p = 0.004) and Dhh epithelial staining was associated with high pT stages (p = 0.003), seminal vesicle invasion (p = 0.03) and bladder neck invasion (p = 0.0008). Negative Shh staining in stromal cells was associated with high Gleason scores (p = 0.015), high pT stages (p = 0.01) and bladder neck invasion (p = 0.04). Concomitant absence of Shh and Dhh expression in stromal cells was an independent prognostic parameter for biological recurrence on multivariate analysis (p = 0.01). Epithelial expression of Shh and Dhh was increased in HTPC compared to HNPC (p = 0.02 and p = 0.04). Interestingly, in vitro, transcript analysis also showed increased expression of these 2 Hh ligands when androgen-sensitive LNCaP cells were maintained in androgen-free medium mimicking hormonal therapy. Epithelial expression of Dhh was increased (p < 0.0001) in HRPC compared to HNPC, while stromal expression of Shh and Dhh was decreased (p < 0.0001). In conclusion, the Hh signalling pathway is associated with pejorative pathological parameters in HNPC and is up-regulated in epithelial cells of HTPC and HRPC. Moreover, the lack of Hh molecules in stromal cells seems to be associated with invasive and hormone-refractory behaviours and suggests specific changes in stromal-epithelial crosstalks during PCa progression.
Collapse
Affiliation(s)
- S Azoulay
- INSERM, Unité 841, Créteil F-94000, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|